To include your compound in the COVID-19 Resource Center, submit it here.

FDA finally approves ozanimod for MS, satisfying first criterion for Bristol-Celgene CVR; launch delayed due to COVID-19

FDA’s approval of Celgene’s multiple sclerosis drug Zeposia ozanimod represents the first domino to fall among three that could lead to a big payout for Celgene’s former shareholders, who would be owed a contingent value right worth billions on top of the $74 billion base price of the company’s acquisition by BMS last year.

The regulatory decision also clears Zeposia to finally enter the market amid muted expectations in

Read the full 686 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers